Jun 22, 2020
Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting
Jun 18, 2020
Lyell Immunopharma and PACT Pharma Announce Research and Clinical Development Partnership
Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
Jun 02, 2020
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
May 14, 2020
Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020
May 13, 2020
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Apr 02, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Feb 28, 2020
Accidental T-cell Discovery Represents "A New Frontier" in Cancer Treatment
Feb 28, 2020
Accidental T-cell Discovery Represents "A New Frontier" in Cancer Treatment
Feb 20, 2020
Global Markets for Cell Therapies & Oncolytic Virus, Forecast to 2026 - Covering Melanoma, Breast, Ovarian & Prostate Cancer Applications
Feb 06, 2020
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Jan 24, 2020
University Hospitals Seidman Cancer Center Treats Its First Glioblastoma Patient With Genetically Modified Poliovirus
Jan 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors
Nov 28, 2019
WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products
Nov 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 12, 2019
Agenus to Host R&D Day November 15, 2019
Nov 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 11, 2019
Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus Therapies
Nov 06, 2019
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer